{
    "data": [
        {
            "id": "4567157",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-30T17:22:04-05:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389406635/image_1389406635.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "97526",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "428666",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4567157-eisai-and-biogens-lecanemab-a-flawed-treatment-for-alzheimers-disease"
            }
        },
        {
            "id": "4566944",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-29T13:41:37-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157399901/image_157399901.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63583",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "428292",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4566944-biogens-alzheimers-drug-likely-to-be-approved-with-warning-labels"
            }
        },
        {
            "id": "4564288",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-13T18:34:12-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367780024/image_1367780024.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: A Comprehensive Look At The Clarity AD Study Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425687",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4564288-biogen-a-comprehensive-look-at-the-clarity-ad-study-results"
            }
        },
        {
            "id": "4561660",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-01T04:05:00-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367780024/image_1367780024.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lecanemab And Alzheimer's: More Data",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4561660-eisai-biogen-lecanemab-alzheimers-data"
            }
        },
        {
            "id": "4551299",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-01T00:37:31-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367780024/image_1367780024.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Second Time's A Charm",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "417668",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4551299-biogen-stock-likely-approval-lecanemab"
            }
        },
        {
            "id": "4551177",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-31T14:51:27-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164478117/image_164478117.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Super-Strong Momentum In A Defensive Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "417402",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4551177-biogen-super-strong-momentum-in-a-defensive-sector"
            }
        },
        {
            "id": "4547037",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-17T16:56:15-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157564919/image_157564919.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: How To Assess Lecanemab's Potential? Invert The Market's Reaction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106720",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414799",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4547037-biogen-how-to-assess-lecanemabs-potential-invert-the-markets-reaction"
            }
        },
        {
            "id": "4544057",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-30T11:56:03-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1218507501/image_1218507501.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "411927",
                            "type": "sentiment"
                        },
                        {
                            "id": "411878",
                            "type": "sentiment"
                        },
                        {
                            "id": "411879",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4544057-eisai-biogen-alzheimers-lecanemab-to-the-rescue"
            }
        },
        {
            "id": "4543835",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-29T12:09:53-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320308217/image_1320308217.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106364",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "411674",
                            "type": "sentiment"
                        },
                        {
                            "id": "411675",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4543835-teamwork-pays-biogen-eisai-announce-positive-results-for-alzheimers-drug"
            }
        },
        {
            "id": "4543674",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-28T16:08:22-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220785248/image_1220785248.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen's Lecanemab Data Blows Alzheimer's Race Open Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "411589",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4543674-biogen-lecanemab-data-blows-alzheimers-race-open-again"
            }
        },
        {
            "id": "4537767",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-29T17:35:54-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368429013/image_1368429013.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: An Uphill Battle Looms",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106720",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "389091",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4537767-an-uphill-battle-looms-for-biogen"
            }
        },
        {
            "id": "4537698",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-29T12:50:23-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/699087378/image_699087378.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Forecasting Suggests Buying At Historical Lows Advisable",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "406515",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4537698-biogen-forecasting-suggests-buying-at-historical-lows-advisable"
            }
        },
        {
            "id": "4536071",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-22T03:05:25-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320308217/image_1320308217.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lecanemab And Biogen's Path To Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105578",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "388772",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4536071-biogen-stock-lecanemab-path-to-growth"
            }
        },
        {
            "id": "4523767",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-16T10:34:30-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Earnings Blitz Includes Netflix, Tesla, AT&T, Philip Morris, And Twitter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523767-stocks-to-watch-earnings-blitz-includes-netflix-tesla-at-and-t-philip-morris-and-twitter"
            }
        },
        {
            "id": "4522750",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-11T15:19:47-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157483234/image_157483234.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen Is Starting To Trend Higher (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101430",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382089",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4522750-biogen-is-starting-to-trend-higher-technical-analysis"
            }
        },
        {
            "id": "4520958",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-29T11:43:15-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/97873871/image_97873871.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen's Alzheimer's Drug Challenges And Opportunities: Aduhelm 'Out' But Lecanemab 'In'?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380562",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520958-biogens-alzheimers-drug-challenges-and-opportunities-aduhelm-out-but-lecanemab-in"
            }
        },
        {
            "id": "4504058",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-27T13:32:48-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307438392/image_1307438392.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Medicare Setback May Trigger Innovation And Partnerships",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106583",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370363",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4504058-biogen-medicare-setback-may-trigger-innovation-and-partnerships"
            }
        },
        {
            "id": "4497534",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-24T10:39:11-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182188515/image_182188515.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Not Yet Time To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366906",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4497534-biogen-not-yet-time-to-buy"
            }
        },
        {
            "id": "4493573",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-07T21:32:02-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300830525/image_1300830525.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Beyond The Doom And Gloom",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "364601",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4493573-biogen-stock-potential-new-drugs"
            }
        },
        {
            "id": "4483580",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-02T12:31:21-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1321083501/image_1321083501.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Evaluating If The Bottom Is In",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "359815",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4483580-biogen-stock-evaluating-if-bottom-in"
            }
        },
        {
            "id": "4478518",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-08T07:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Big Banks Report Earnings, AMD-Xilinx Deal Drama, Huge Conferences In Retail And Healthcare",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478518-stocks-to-watch-big-banks-report-earnings-amd-xilinx-deal-drama-huge-conferences-in-retail-and-healthcare"
            }
        },
        {
            "id": "4478198",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-06T07:10:30-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/865618914/image_865618914.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen's ADUHELM Alzheimer's Pricing: Fiasco Or Second-Level Thinking?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "355558",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478198-biogen-aduhelm-alzheimers-pricing-fiasco-second-level-thinking"
            }
        }
    ]
}